PMID- 23240751
OWN - NLM
STAT- MEDLINE
DCOM- 20130607
LR  - 20121217
IS  - 1750-7448 (Electronic)
IS  - 1750-743X (Linking)
VI  - 4
IP  - 12
DP  - 2012 Dec
TI  - Improved IgG3 levels and reduced infection rate in a woman with CVID switched 
      from intravenous to subcutaneous immunoglobulin therapy.
PG  - 1835-9
LID - 10.2217/imt.12.130 [doi]
AB  - AIM: To report the interesting case of a patient with common variable immune 
      deficiency disease who demonstrated varied responses to intravenous (IV) and 
      subcutaneous (SC) immunoglobulin (Ig) therapy with regard to both infection 
      frequencies and IgG3 subclass determinations. PATIENT & METHODS: As part of 
      routine medical care, the author monitored total and IgG subclass levels, along 
      with infection frequencies in a 35-year-old woman, with recurrent sinopulmonary 
      infections diagnosed with common variable immune deficiency disease. RESULTS: 
      During treatment with IVIg, the patient's annual rate of infections decreased, 
      although she experienced severe headaches. After being switched to daily SCIg 
      therapy, the headaches stopped, and her annual infection rate declined further. 
      Her IgG3 levels, which were undetectable during IVIg therapy, increased 
      substantially during SCIg treatment. CONCLUSION: The reason for the observed 
      correlation between IgG3 level restoration and a decline in infection rate after 
      being switched to SCIg therapy is not entirely clear. At the minimum, it may 
      suggest that IgG3 levels may be a simple and useful surrogate marker to monitor 
      Ig replacement sufficiency in certain patients.
FAU - Shapiro, Ralph S
AU  - Shapiro RS
AD  - Midwest Immunology Clinic & Infusion Center, MN 55446, USA. 
      rshapiro@midwestimmunology.com
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Immunotherapy
JT  - Immunotherapy
JID - 101485158
RN  - 0 (Biomarkers, Pharmacological)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulins)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Adult
MH  - Biomarkers, Pharmacological/blood
MH  - Clinical Protocols
MH  - Common Variable Immunodeficiency/complications/*drug therapy/immunology
MH  - Drug Substitution
MH  - Female
MH  - Headache/etiology/prevention & control
MH  - Humans
MH  - Immunoglobulin G/blood
MH  - Immunoglobulins/*administration & dosage
MH  - Immunoglobulins, Intravenous/*administration & dosage/adverse effects
MH  - Injections, Subcutaneous
MH  - Recurrence
MH  - Respiratory Tract Infections/etiology/immunology/*prevention & control
EDAT- 2012/12/18 06:00
MHDA- 2013/06/08 06:00
CRDT- 2012/12/18 06:00
PHST- 2012/12/18 06:00 [entrez]
PHST- 2012/12/18 06:00 [pubmed]
PHST- 2013/06/08 06:00 [medline]
AID - 10.2217/imt.12.130 [doi]
PST - ppublish
SO  - Immunotherapy. 2012 Dec;4(12):1835-9. doi: 10.2217/imt.12.130.